Atazanavir/cobicistat

Atazanavir/cobicistat
Combination of
AtazanavirHIV protease inhibitor
CobicistatCytochrome P450 (CYP3A) inhibitor
Clinical data
Trade namesEvotaz
AHFS/Drugs.comProfessional Drug Facts
License data
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Atazanavir/cobicistat, sold under the brand name Evotaz, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS.[2][3] It contains atazanavir and cobicistat.[2][3] Atazanavir is an HIV protease inhibitor and cobicistat is an inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A family.[2]

Atazanavir/cobicistat was approved by the Food and Drug Administration (FDA) for medical use in United States in January 2015.[4][5] It was approved for medical use in the European Union in July 2015.[3]

Medical uses

Atazanavir/cobicistat is indicated for use in combination with other antiretroviral agents for the treatment of HIV‑1 infection in people weighing at least 35 kilograms (77 lb).[2][3]

References

  1. ↑ "Evotaz 300 mg/150 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 9 July 2021.
  2. 1 2 3 4 5 "Evotaz- atazanavir and cobicistat tablet". DailyMed. Retrieved 25 May 2021.
  3. 1 2 3 4 5 "Evotaz EPAR". European Medicines Agency (EMA). Retrieved 25 May 2021.
  4. ↑ "U.S. Food and Drug Administration Approves Bristol-Myers Squibb's Evotaz (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults" (Press release). Bristol-Myers Squibb.
  5. ↑ "Evotaz (atazanavir and cobicistat) Tablet". U.S. Food and Drug Administration (FDA). 15 April 2016. Retrieved 25 May 2021. Lay summary (PDF). {{cite web}}: Cite uses deprecated parameter |lay-url= (help)


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.